Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation

Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?

(2022) Qidi Ying et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes

(2021) Tingting Li et al.   BMC Cardiovascular Disorders

The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity

(2021) Daan M. van Velzen et al.   ATHEROSCLEROSIS

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

(2021) Maria Pia Adorni et al.   Cells

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting

(2021) Roberto Scicali et al.   ACTA DIABETOLOGICA

High-density lipoproteins, reverse cholesterol transport and atherogenesis

(2021) Henry J. Pownall et al.   Nature Reviews Cardiology

HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research

(2021) Anand Rohatgi et al.   CIRCULATION

Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

(2021) Patrice Marques et al.   BIOMEDICINE & PHARMACOTHERAPY

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

(2021) Xiaoyue Ge et al.   Biomed Research International

Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation

(2021) Sabina Ugovšek et al.   Biomolecules

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis

(2021) Jane J. Lee et al.   Frontiers in Cardiovascular Medicine

Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk

(2020) María Trinidad Soria-Florido et al.   CIRCULATION

PCSK9 inhibitors for treating hypercholesterolemia

(2020) Andrea Pasta et al.   EXPERT OPINION ON PHARMACOTHERAPY

Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study

(2020) Daniela Greco et al.   Journal of Clinical Medicine

PCSK9 and LRP5 in macrophage lipid internalization and inflammation

(2020) Lina Badimon et al.   CARDIOVASCULAR RESEARCH

An Update on the Role of PCSK9 in Atherosclerosis

(2020) Ece Yurtseven et al.   Journal of Atherosclerosis and Thrombosis

Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk

(2020) Cécile Ingueneau et al.   VASCULAR PHARMACOLOGY

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

High density lipoprotein function is reduced in patients affected by genetic or idiopathic hypogonadism

(2019) Maria Pia Adorni et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads

(2019) Yuna Horiuchi et al.   BIOSCIENCE REPORTS

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease

(2019) Maria Pia Adorni et al.   Frontiers in Aging Neuroscience

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease

(2019) Sabina A. Murphy et al.   JAMA Cardiology

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

PCSK9 inhibitors and cardiovascular outcomes

(2019) Daniel Steffens et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

(2018) Sreeneeranj Kasichayanula et al.   CLINICAL PHARMACOKINETICS

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

(2018) Knut Tore Lappegård et al.   TRANSFUSION AND APHERESIS SCIENCE

Influence of HDL particles on cell-cholesterol efflux under various pathological conditions

(2017) Bela F. Asztalos et al.   JOURNAL OF LIPID RESEARCH

Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction

(2017) Francesca Zimetti et al.   JOURNAL OF LIPID RESEARCH

Mechanisms of foam cell formation in atherosclerosis

(2017) Dimitry A. Chistiakov et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia

(2015) Masatsune Ogura et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HDL Cholesterol Efflux Capacity and Cardiovascular Events

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

(2015) Nicoletta Ronda et al.   Arthritis & Rheumatology

Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study

(2015) Danish Saleheen et al.   Lancet Diabetes & Endocrinology

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

(2014) Anand Rohatgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

(2013) Nicoletta Ronda et al.   ANNALS OF THE RHEUMATIC DISEASES

Importance of Evaluating Cell Cholesterol Influx With Efflux in Determining the Impact of Human Serum on Cholesterol Metabolism and Atherosclerosis

(2013) Ginny L. Weibel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Foam cells in atherosclerosis

(2013) Xiao-Hua Yu et al.   CLINICA CHIMICA ACTA

The role of cholesterol efflux in mechanisms of endothelial protection by HDL

(2012) Hamish C. Prosser et al.   CURRENT OPINION IN LIPIDOLOGY

Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis

(2012) Marit S. Nenseter et al.   Journal of Clinical Lipidology

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis

(2012) M. P. Adorni et al.   JOURNAL OF LIPID RESEARCH

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux

(2008) Sandhya Sankaranarayanan et al.   JOURNAL OF LIPID RESEARCH